Description
Glycoprotein IIb/IIIa inhibitors represent a new promising class of antiplatelet medications. Their use in acute coronary syndromes and for patients undergoing percutaneous coronary intervention has been the subject of a number of large controlled trials using both the intravenous and the oral forms. In this review, we present a systematic overview of these trials.
Resources
| Name | Format | Description | Link |
|---|---|---|---|
| Official Government Data Source | HTML | Visit the original government dataset for complete information, documentation, and data access. | Open resource |